Connection

Yuri Peterson to Antineoplastic Agents

This is a "connection" page, showing publications Yuri Peterson has written about Antineoplastic Agents.
Connection Strength

0.660
  1. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J Biol Chem. 2006 May 05; 281(18):12445-50.
    View in: PubMed
    Score: 0.156
  2. Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs. Molecules. 2022 Jun 08; 27(12).
    View in: PubMed
    Score: 0.120
  3. Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021 08; 162(2):463-473.
    View in: PubMed
    Score: 0.105
  4. Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity. J Med Chem. 2020 05 28; 63(10):5501-5525.
    View in: PubMed
    Score: 0.104
  5. Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status. J Med Chem. 2018 03 22; 61(6):2589-2603.
    View in: PubMed
    Score: 0.090
  6. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013 01; 5(1):105-21.
    View in: PubMed
    Score: 0.062
  7. Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. Cancer Res. 2019 01 01; 79(1):231-241.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.